{
  "pathway": "Pharmacy First - Impetigo (non-bullous, ≥1 year)",
  "metadata": {
    "version": "1.0",
    "lastUpdated": "2025-02-15",
    "sources": [
      "https://clinicalpathways.uk/pharmacy/impetigo/",
      "https://cks.nice.org.uk/topics/impetigo/",
      "https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN01010-3a.-Impetigo-hydrogen-peroxide-cream-protocol-Pharmacy-First.pdf",
      "https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN01010-3b.-Impetigo-fusidic-acid-cream-patient-group-direction-Pharmacy-First.pdf",
      "https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN01010-3c.-Impetigo-flucloxacillin-patient-group-direction-Pharmacy-First.pdf",
      "https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN01010-3d.-Impetigo-clarithromycin-patient-group-direction-Pharmacy-First.pdf",
      "https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN01010-3e.-Impetigo-erythromycin-patient-group-direction-Pharmacy-First.pdf"
    ],
    "niceGuideline": "NICE CKS Impetigo"
  },
  "notes": [
    "Scope: non-bullous impetigo in adults and children ≥1 year. Exclude bullous disease, recurrent impetigo (≥2 episodes in the same year), widespread systemic illness, and pregnant people <16 years.",
    "Record lesion count/location, crusting/oozing stage, systemic features, previous topical/oral therapy, allergies, pregnancy status, and safeguarding concerns in the Pharmacy First consultation record.",
    "Advise strict hygiene (avoid sharing towels, bedding, razors; keep nails short; wash hands frequently; gently remove crusts with warm soapy water before applying topical therapy).",
    "Inform patients that impetigo is highly contagious until lesions crust/heal; exclude from nurseries/schools until lesions are dry or 48 hours after antibiotics are started.",
    "Share the British Association of Dermatologists impetigo leaflet and reinforce when to seek urgent care (rapid spread, fever, lymphangitis, orbital involvement)."
  ],
  "decisionTree": {
    "id": "complication_screen",
    "type": "decision",
    "title": "Consider the risk of deterioration or serious illness",
    "question": "Does the patient have complications or high-risk features?",
    "details": {
      "systemicOrHighRisk": [
        "Systemically very unwell (fever, rigors, tachycardia, hypotension, NEWS2 trigger).",
        "Signs of cellulitis, lymphangitis, abscess, periorbital involvement, or rapidly spreading erythema.",
        "Evidence of bullous impetigo, eczema herpeticum, varicella zoster, or other differential diagnoses needing medical review.",
        "Recurrent impetigo in the same year, neonates, immunosuppressed individuals, or suspected sepsis."
      ],
      "safeguarding": [
        "Suspected neglect/poor hygiene unable to self-manage.",
        "Failure to respond to prior oral antibiotics.",
        "Consider pregnancy (particularly <16 years) outside Pharmacy First scope."
      ]
    },
    "yes": {
      "id": "urgent_referral",
      "type": "action",
      "title": "Onward referral required",
      "actions": [
        "Consider NEWS2 and arrange urgent GP, community pediatrics, or A&E/999 assessment as appropriate.",
        "Do not supply under PGD—provide written safety-netting and document escalation.",
        "Advise isolation of affected areas and reinforce infection control while awaiting assessment."
      ],
      "safetyNet": true
    },
    "no": {
      "id": "typical_features",
      "type": "decision",
      "title": "Confirm clinical diagnosis",
      "question": "Does the presentation follow typical impetigo clinical features?",
      "details": {
        "typicalFeatures": [
          "Vesicles that rupture to form honey-coloured crusts on an erythematous base.",
          "Lesions clustered on exposed areas (face, perioral region, limbs) with minimal surrounding cellulitis.",
          "Patient systemically well or only mild malaise; no deep tissue involvement.",
          "History of minor trauma/eczema causing portal of entry."
        ],
        "considerAlternatives": [
          "Herpes simplex, eczema herpeticum, varicella, folliculitis, scabies, contact dermatitis, insect bites."
        ]
      },
      "yes": {
        "id": "lesion_gate",
        "type": "decision",
        "title": "Gateway point",
        "question": "Does the patient have ≤3 lesions/clusters present (localised)?",
        "details": {
          "countGuidance": [
            "Localised disease usually means three or fewer discrete lesions or closely grouped clusters.",
            "Document lesion sites (perioral, limbs, trunk) and whether eyes/nose are affected.",
            "If lesions are near the eyes or lips consider suitability of hydrogen peroxide vs fusidic acid."
          ]
        },
        "yes": {
          "id": "hydrogen_first_line",
          "type": "decision",
          "title": "Localised non-bullous impetigo",
          "question": "Is hydrogen peroxide 1% cream suitable and available?",
          "details": {
            "useHydrogenPeroxide": [
              "First-line for localised lesions when skin is intact apart from superficial crusts.",
              "Apply thinly to affected areas after gently soaking off crusts, twice daily for 5 days.",
              "Continue good hygiene measures to reduce transmission."
            ],
            "notAppropriate": [
              "Lesions close to the eyes or mucosa where hydrogen peroxide may irritate.",
              "Previous 5-day hydrogen peroxide course failed and impetigo remains localised.",
              "Product out of stock/unavailable."
            ]
          },
          "yes": {
            "id": "hydrogen_peroxide_treatment",
            "type": "treatment",
            "title": "Hydrogen peroxide 1% cream (first line)",
            "drug": "Hydrogen peroxide 1% cream",
            "durationDays": 5,
            "dose": "Apply thinly to affected skin twice daily for 5 days; cleanse crusts with warm soapy water before application.",
            "formulations": [
              "Hydrogen peroxide 1% (10 mg/1 g) cream such as Crystacide®"
            ],
            "route": "Topical application to intact surrounding skin.",
            "legalCategory": "GSL supplied under Pharmacy First protocol",
            "plus": [
              "Advise on strict hand hygiene, no sharing of towels/bedding, regular laundering at 60 °C.",
              "Do not cover lesions with occlusive dressings; keep nails short to prevent excoriation."
            ],
            "followUp": "If lesions worsen, spread rapidly, or fail to improve after 5 days of treatment, reassess and consider second-line therapy or referral.",
            "safetyNet": true
          },
          "no": {
            "id": "fusidic_second_line",
            "type": "treatment",
            "title": "Fusidic acid 2% cream (second line topical)",
            "drug": "Fusidic acid 2% cream",
            "durationDays": 5,
            "dose": "Apply three to four times daily to affected areas for 5 days (after gently removing crusts).",
            "formulations": [
              "Fusidic acid 2% cream 15 g (tubes)",
              "Fusidic acid 2% ointment (when cream unavailable)"
            ],
            "route": "Topical",
            "legalCategory": "POM (supplied under PGD)",
            "plus": [
              "Reserve for cases where hydrogen peroxide is unsuitable (e.g. peri-ocular involvement) or has failed despite adherence.",
              "Continue infection prevention measures and alert patient about potential local irritation."
            ],
            "followUp": "If no improvement after 5 days or impetigo spreads beyond localised area, stop treatment and arrange medical review.",
            "safetyNet": true,
            "referralIfWorsen": true
          }
        },
        "no": {
          "id": "widespread_branch",
          "type": "decision",
          "title": "Widespread non-bullous impetigo",
          "question": "Does the patient have ≥4 lesions/clusters requiring oral therapy?",
          "details": {
            "oralTherapy": [
              "Indicated when impetigo is spreading, involves multiple body sites, or the patient is in a setting with high transmission risk.",
              "Document penicillin allergy status via National Care Record, SCR, or reliable history.",
              "Ensure adherence support (dosing three to four times daily) and reinforce self-care."
            ]
          },
          "yes": {
            "id": "penicillin_allergy_check",
            "type": "decision",
            "title": "Penicillin allergy?",
            "question": "Is there a confirmed penicillin allergy?",
            "yes": {
              "id": "pregnancy_check",
              "type": "decision",
              "title": "Pregnancy status for macrolide choice",
              "question": "Is the adult patient pregnant (or pregnancy suspected)?",
              "yes": {
                "id": "erythromycin_pregnancy",
                "type": "treatment",
                "title": "Erythromycin (penicillin allergy + pregnancy)",
                "drug": "Erythromycin",
                "durationDays": 5,
                "dose": {
                  "Adults": "500 mg four times daily (or 1 g twice daily modified-release) for 5 days."
                },
                "formulations": [
                  "Tablets/capsules 250 mg, 500 mg",
                  "Oral suspension 125 mg/5 mL, 250 mg/5 mL"
                ],
                "route": "Oral",
                "legalCategory": "POM (PGD)",
                "plus": [
                  "Take with meals to improve tolerance; common adverse effects include nausea and abdominal cramps.",
                  "Advise patients to complete the 5-day course and report cholestatic jaundice symptoms."
                ],
                "followUp": "Contact GP if no improvement within 2–3 days or sooner if systemic symptoms develop.",
                "safetyNet": true,
                "referralIfWorsen": true
              },
              "no": {
                "id": "clarithromycin_branch",
                "type": "treatment",
                "title": "Clarithromycin (penicillin allergy)",
                "drug": "Clarithromycin",
                "durationDays": 5,
                "dose": {
                  "Children 1–11 years by weight": {
                    "≤8 kg": "7.5 mg/kg twice daily",
                    "8–11 kg": "62.5 mg twice daily",
                    "12–19 kg": "125 mg twice daily",
                    "20–29 kg": "187.5 mg twice daily",
                    "30–40 kg": "250 mg twice daily"
                  },
                  "≥12 years and adults": "250 mg twice daily"
                },
                "formulations": [
                  "Tablets 250 mg, 500 mg",
                  "Suspension 125 mg/5 mL, 250 mg/5 mL"
                ],
                "route": "Oral (with or without food; take with water).",
                "legalCategory": "POM (PGD)",
                "plus": [
                  "Avoid with potent CYP3A4 inhibitors; check for QT prolongation risk and statin use.",
                  "Warn about potential taste disturbance or GI upset; encourage adherence for full 5 days."
                ],
                "followUp": "Reassess if lesions worsen, fail to improve within 2–3 days, or patient develops systemic features.",
                "safetyNet": true,
                "referralIfWorsen": true
              }
            },
            "no": {
              "id": "flucloxacillin_branch",
              "type": "treatment",
              "title": "Flucloxacillin (no penicillin allergy)",
              "drug": "Flucloxacillin",
              "durationDays": 5,
              "dose": {
                "Children 1–11 years": "12.5 mg/kg (max 500 mg) four times daily",
                "≥12 years and adults": "500 mg four times daily"
              },
              "formulations": [
                "Capsules 250 mg, 500 mg",
                "Oral solution 125 mg/5 mL, 250 mg/5 mL"
              ],
              "route": "Oral (preferably on an empty stomach).",
              "legalCategory": "POM (PGD)",
              "plus": [
                "Explain importance of evenly spaced doses and completing the course even if lesions improve quickly.",
                "Advise monitoring for hepatic dysfunction or rash; stop and seek advice if cholestatic jaundice occurs."
              ],
              "followUp": "Review if no improvement within 2–3 days, worsening pain, fever, or lymphangitis.",
              "safetyNet": true,
              "referralIfWorsen": true
            }
          },
          "no": {
            "id": "reassess_extent",
            "type": "action",
            "title": "Unable to confirm widespread criteria",
            "actions": [
              "Reassess lesion count and distribution; consider localised pathway or alternative diagnoses.",
              "If lesions are crusting but patient is high risk (e.g. immunosuppressed), seek prescriber advice.",
              "Do not supply oral antibiotics unless PGD criteria are met; provide self-care guidance meanwhile."
            ],
            "safetyNet": true
          }
        }
      },
      "no": {
        "id": "alt_diagnosis",
        "type": "action",
        "title": "Impetigo less likely",
        "actions": [
          "Consider differentials (HSV, eczema herpeticum, insect bites, scabies, contact dermatitis).",
          "Arrange appropriate tests or referral; provide safety-netting if diagnosis uncertain.",
          "Avoid PGD supply until diagnosis confirmed."
        ],
        "safetyNet": true
      }
    }
  }
}
